ImmunityBio IBRX enters the post-earnings stretch with the stock at $7.72 (as of May 28, 2026) and a six to12 month price target of $8.25. After a 289.9% year-to-date surge, the setup is less about “what’s next” and more about what has already been priced in.

The base case is an in-line performance profile tied to Anktiva’s commercial trajectory, with near-term upside requiring continued proof that demand is still accelerating after the run.

IBRX Stock Snapshot and What It Implies

IBRX has already delivered a sharp rerating, and the valuation reflects it. The shares are trading at 23.41x forward twelve-month sales versus 1.96x for the Zacks sub-industry, 2.12x for the Zacks sector and 5.25x for the S&P 500. That…